Skip to content

Sildenafil Vaginal Gel Co-treatment With Clomiphene Citrate in Infertile Women With Thin Endometrium

Effect of Sildenafil Vaginal Gel Co-treatment With Clomiphene Citrate on Endometrial Thickness in Infertile Women With Prior Clomiphene Citrate Failure Due to Thin Endometrium: a Prospective Self-controlled Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02710981
Enrollment
42
Registered
2016-03-17
Start date
2015-06-30
Completion date
2016-01-31
Last updated
2020-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anovulation

Keywords

Sildenafil vaginal gel, endometrium, clomiphene, anovulation

Brief summary

This is a prospective self controlled clinical trial. Women with clomiphene Citrate failure, and thin endometrium were recruited (N = 42). In their 6th (Clomiphene citrate only) cycle, women continued on Clomiphene citrate 100 mg/ day for 5 days, and had sonographic measurement of their endometrial thickness , and Doppler evaluation of their uterine arteries on the day of HCG administration. In 7th cycle, women (N = 36) were given usual dose of Clomiphene citrate supplemented with sildenafil vagina gel (5 gm, containing 50 mg sildenafil) twice daily from cycle day 8 till the day of HCG injection. Endometrial thickness and uterine artery Doppler were measured on the day of HCG administration.

Detailed description

Study design: This is a prospective self-controlled clinical trial. Study subjects: Investigators counseled and recruited 42 infertile women who had been diagnosed with anovulatory infertility, with normal baseline FSH, LH, and free testosterone levels, patent tubes on hysterosalpingography, and normal male semen analysis. By the time they were enrolled in the study, all women had already completed 5 ovulatory cycles of Clomiphene citrate induction (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) but without conception (clomiphene citrate failure) with thin endometrium (\<8mm) in at least 3 cycles. Ovulation was documented sonographically, and with day-21 serum progesterone exceeding 5 ng/ ml in all cases. Exclusion criteria: Women with major medical problems, male factor infertility, endocrine abnormalities such as hyperprolactinemia or abnormal thyroid functions, prior ovarian or adnexal surgery, or organic pelvic pathology were not included in the study. Intervention: Sixth cycle (Clomiphene citrate only): Enrolled cases were asked to continue with Clomiphene citrate induction ( at the same dose) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG administration ( when follicular diameter reached 18 mm). Endometrial thickness and Uterine artery Doppler assessment were done in the late proliferative phase ( Day of HCG injection). Seventh cycle ( Sildenafil vaginal gel and Clomiphene cycle): Those who didn't conceive on the sixth cycle (41 women) were asked to have an extra (7th) cycle in which they were prescribed the usual dose of Clomiphene citrate in addition to sildenafil vaginal gel. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose. The dose was 5 g gel containing 50 mg sildenafil, applied vaginally twice daily from cycle day 8 to Day of HCG injection. The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel. Evaluation of the study end points: On day of HCG injection (main follicular diameter of 18 mm) in the 6th, and 7th cycles, women came for follow up and had transvaginal sonographic assessment of their endometrial thickness. Investigators have measured the maximal distance spanning endometrial- myometrial interphase on each endometrial stripe in a sagittal plane in the fundus of the uterus. In addition, Transvaginal Doppler examination was also done on the same visit to evaluate the pulsatility indices of both uterine arteries. When the leading follicle reached 18 mm in diameter, 5000 IU of HCG was prescribed for IM injection. Although pregnancy rate was not a primary outcome measure in the study, investigators detected pregnancy in 3 cases in the cohort of 36 cases of infertile women with clomiphene failure in which sildenafil gel was added as an adjuvant. Pregnancy was diagnosed with a B-HCG value above 100 mIU/ml, and confirmed later with ultrasound. Statistics: Data were analyzed using SPSS program ver. 17 using Student-t-test and Fisher's exact test for comparing data in the 6th and 7th cycles, as appropriate.

Interventions

DRUGclomiphene citrate

Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).

DRUGSildenafil vaginal gel

In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Women with clomiphene citrate failure (defined as at least prior 5 ovulatory cycles with clomiphene citrate, with no conception), * persistently thin endometrium (less than 8 mm in at least 3 cycles). * normal baseline FSH, LH, and free testosterone levels, patent tubes on hysterosalpingography, and normal male semen analysis

Exclusion criteria

* Women with major medical problems, * male factor infertility, * endocrine abnormalities such as hyperprolactinemia or abnormal thyroid functions, * prior ovarian or adnexal surgery, or organic pelvic pathology

Design outcomes

Primary

MeasureTime frameDescription
Endometrial ThicknessDay of HCG administrationTransvaginal sonographic measurement of maximal distance spanning endometrial- myometrial interphase on each endometrial stripe in a sagittal plane in the fundus of the uterus

Secondary

MeasureTime frameDescription
Uterine Blood FlowDay of HCG administrationDoppler ultrasound is used to measure the pulsatility index in both uterine arteries. Pulsatility index is a measure of the arterial resistance to blood flow. The higher the value of the pulsatility index, the more resistant the uterine arteries are, and hence the worst the outcome.
Clinical Pregnancy RateAt the end of a 28-day menstrual cycle.Identifying pregnancy through positive urinary HCG test plus sonographic detection of cardiac pulsations

Participant flow

Pre-assignment details

As this is a self controlled clinical trial, participants in the clomiphene citrate only arm (6th ovulation induction cycle) are the same participant in the clomiphene citrate plus sildenafil vaginal gel arm (7th ovulation induction cycle).

Participants by arm

ArmCount
Clomiphene Citrate Only Group (6th Ovulation Induction Cycle)
Infertile women who have completed 5 cycles of clomiphene citrate with successful ovulation, thin endometrium and no pregnancy who are attempting a 6th cycle of clomiphene citrate.
41
Total41

Baseline characteristics

CharacteristicClomiphene Citrate Only Group (6th Ovulation Induction Cycle)
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
41 Participants
Age, Continuous26.8 years
STANDARD_DEVIATION 2.8
Race and Ethnicity Not Collected— Participants
Region of Enrollment
Egypt
41 participants
Serum FSH4.5 U/L
STANDARD_DEVIATION 1.5
Sex: Female, Male
Female
41 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 411 / 36
serious
Total, serious adverse events
0 / 420 / 41

Outcome results

Primary

Endometrial Thickness

Transvaginal sonographic measurement of maximal distance spanning endometrial- myometrial interphase on each endometrial stripe in a sagittal plane in the fundus of the uterus

Time frame: Day of HCG administration

ArmMeasureValue (MEAN)Dispersion
Clomiphene Citrate Only Group (6th Ovulation Induction Cycle)Endometrial Thickness6.6 millimeterStandard Deviation 1.4
Clomiphene Citrate Plus Sildenafil Vaginal Gel (7th Ovulation)Endometrial Thickness9.3 millimeterStandard Deviation 3.1
Secondary

Clinical Pregnancy Rate

Identifying pregnancy through positive urinary HCG test plus sonographic detection of cardiac pulsations

Time frame: At the end of a 28-day menstrual cycle.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Clomiphene Citrate Only Group (6th Ovulation Induction Cycle)Clinical Pregnancy Rate0 Participants
Clomiphene Citrate Plus Sildenafil Vaginal Gel (7th Ovulation)Clinical Pregnancy Rate3 Participants
Secondary

Uterine Blood Flow

Doppler ultrasound is used to measure the pulsatility index in both uterine arteries. Pulsatility index is a measure of the arterial resistance to blood flow. The higher the value of the pulsatility index, the more resistant the uterine arteries are, and hence the worst the outcome.

Time frame: Day of HCG administration

ArmMeasureValue (MEAN)Dispersion
Clomiphene Citrate Only Group (6th Ovulation Induction Cycle)Uterine Blood Flow2.4 indexStandard Deviation 0.8
Clomiphene Citrate Plus Sildenafil Vaginal Gel (7th Ovulation)Uterine Blood Flow1.6 indexStandard Deviation 1.3

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026